Adalimumab for orbital myositis in a patient with Crohn’s disease who discontinued infliximab: a case report and review of the literature by unknown
Verma et al. BMC Gastroenterology 2013, 13:59
http://www.biomedcentral.com/1471-230X/13/59CASE REPORT Open AccessAdalimumab for orbital myositis in a patient with
Crohn’s disease who discontinued infliximab:
a case report and review of the literature
Sanam Verma, Karen I Kroeker and Richard N Fedorak*Abstract
Background: Orbital myositis is a rare extra-intestinal manifestation of inflammatory bowel disease. Seventeen
cases of Crohn’s disease associated orbital myositis and 3 cases of ulcerative colitis associated orbital myositis have
been reported in the published literature since 1970. We report the use of adalimumab (Abbott, Canada, Inc.) for
orbital myositis in a patient with Crohn’s disease who discontinued infliximab (Janssen, Canada, Inc.) and review of
the published literature.
Case presentation: A 35 year-old male with a 7-year history of Crohn’s disease was treated with an ileocolonic
resection and re-anastomosis followed by infliximab which maintained full endoscopic and clinical remission for
four years. After stopping the infliximab for infusion-related reactions he presented with 3-day history of severe
right eye pain, pain with ocular movement, proptosis, and conjunctival injection. He had no intestinal symptoms
and endoscopic assessment revealed no active luminal disease. CT of the orbit revealed an enlarged right medial
rectus muscle with tendonous involvement and a diagnosis of orbital myositis was made. Treatment with 80 mg
per day prednisone with tapering dose and adalimumab, induction and maintenance, resulted in rapid resolution
of the orbital myositis and ocular symptoms with no recurrences on follow-up at 10 months.
Conclusions: The current case demonstrates a rare extraintestinal manifestation of Crohn’s disease, orbital myositis,
and its temporal relationship to the discontinuance of infliximab therapy and its successful treatment, without
recurrence with tapering prednisone and adalimumab.
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Extra-intestinal manifestations of Crohn’s disease (CD)
are inflammatory manifestations that occur outside the
gastrointestinal tract. Up to 30% of Crohn’s patients may
present with multiple extraintestinal manifestations with
the occurrence of one increasing the chances of others
[1]. Ocular manifestations of CD occur infrequently with
a prevalence rate of less than 10%; most of these cases
being episcleritis and uveitis [2]. Orbital myositis (OM)
is a very rare ocular extraintestinal manifestation of CD.
A literature review revealed that in a sample of 498 pa-
tients with Crohn’s only one patient had OM [3]. To* Correspondence: richard.fedorak@ualberta.ca
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reproduction in any medium, provided the ordetermine the full published literature relating to OM as a
complication of CD the PubMed and Medline databases
were searched for relevant literature. Seventeen previous
cases of Crohn’s related OM have been reported in litera-
ture. Only one previous study looked at adalimumab use in
recurrent OM related to CD [4-9]. Therefore, in this patient
group the use of adalimumab needs to be further explored.
Case presentation
A 35-year-old Caucasian male was diagnosed with long
segment ileal and extensive colonic CD in 2005, follow-
ing a 10-year history of intermittent abdominal pain,
cramps, and diarrhea. At diagnosis patient was placed on
mesalamine (4 g/d), corticosteroids (prednisone 40 mg/d
tapering over 12 weeks to zero) and azathioprine
(150 mg/d) as induction therapy. He achieved clinicalLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Patient at presentation with erythema and edema of
the right upper eyelids, fullness of superior sulcus suggestive
of proptosis.
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episode of small bowel obstruction and underwent an
ileal resection with an ileocolonic anastomosis.
Post operatively he was treated with azathioprine
150 mg/d; however, markedly elevated liver enzymes
led to the discontinuance of the azathioprine. Within 6
months of stopping the azathioprine he developed re-
current abdominal pain and diarrhea and colonoscopy
confirmed anastomotic recurrence of his disease. He
was then started on infliximab (5 mg/kg) monotherapy
with an induction regime of 0, 2, 6 weeks followed by
maintenance treatment every 8 weeks. He achieved a
full remission, confirmed endoscopically, for four years.Figure 2 Computerize tomography of the orbits revealed enlarged rig
(small arrows) and mild proptosis (large arrow). No fat stranding or scleAfter his 28th infliximab infusion, he began to develop
significant arthralgia and maculaopapular skin rashes
on the dorsum of his hands and arms, which worsened
after each infliximab infusion. There was no biochem-
ical evidence of disease activity; hemoglobin, C-reactive
protein, platelet count, serum iron and ferritin were
normal. The infliximab was discontinued and endoscopic
restaging and assessment for adalimumab insurance
coverage was arranged. 6-mercaptopurine (75 mg/d) was
started after discontinuation of the inflximab while the
endoscopic restaging and assessment was pending. How-
ever, the 6-mercaptopurine was stopped after 3 weeks
due to severe nausea and fatigue. The patient’s occupa-
tion prevented him from completing the restaging and
insurance assessment and during this time he was on no
therapy for his CD.
Six weeks after stopping the 6-mercaptopurine and
13 weeks after stopping the infliximab the patient
presented to the emergency department with a three-day
history of severe right eye pain. Examination revealed an
uncorrected visual acuity was 20/25 OD and 20/20 OS.
Intraocular pressure of the right eye was slightly elevated,
the right upper eyelid was swollen and the conjunctiva
injected (Figure 1). The right globe was 1.5 mm anterior
than the left. Pupillary response to light was normal and
there was no relative afferent pupillary defect. The pa-
tient had limited extraocular movement and significant
pain on abduction and adduction of the right eye. No
optic nerve abnormalities were noted, specifically no
hyperaemia of the optic nerve or nerve fiber layer edema.
The patient was afebrile and had normal hemoglobin,
white blood cell count, C-reactive protein, iron studiesht medial rectus muscle with tendonous insertion involvement
ral thickening was noted.
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the orbits revealed enlarged right medial rectus muscle
with tendonous involvement, mild proptosis, no fat
stranding or sclerotic changes (Figure 2), and no sinus
opacification was noted. The remaining physical exam
was normal. Diagnosis of idiopathic orbital inflammatory
syndrome, OM subtype, was made based on clinical find-
ings and imaging. The patient was started on prednisone
80mg/d and tapered over 4 weeks. Within 48 hours there
was improvement in the orbital pain, redness, and swell-
ing and the patient was then started on adalimumab with
induction dosing of 160 mg, 80 mg, followed by 40 mg
weekly and methotrexate 12.5 mg once weekly as a
standard combination therapy. Colonoscopy (after initi-
ation of treatment of the OM) did not demonstrate active












Bennion/2012 [10] 63 M UC Infliximab CT
Pimentel/2012 [9] 55 F CD Sulfasalazine Gado
Hernandez-Garfella/
2011 [6]
32 F CD Corticosteroids MRI
Kondolt/2011 [11] 11 F CD None CT M
Bourikas/2010 [7] 35 F CD None MRI
Culver/2008 [4] 23 F CD Methotrexate Infliximab Gado
Ramahlo/2008 [12] 40 F CD Methotrexate
6-mercaptopurine
MRI
Leibovitch/2005 [8] 44 M CD Unknown CT
Macarez/2005 [13] 32 M UC Mesalamine CT M
Garrity/2004 [14] 34 F CD Prednisone MRI
Garrity/2004 [14] 27 F CD Prednisone methotrexate
6 MP
Unkn
Maalouf/2001 [15] 48 F CD None CT
Jain/2001 [16] 43 F UC Unknown MRI
Durno/1997 [17] 12 F CD None MRI
Squires/1992 [18] 20 M CD None CT
Smith//1992 [19] 54 F CD Unknown CT
Verbraeken/1984 [20] 38 F CD Sulfasalazine Unkn
Weinstein/1984 [21] 17 F CD None Unkn
Camfield/1982 [22] 15 F CD None Unkn
Greenstein/1976 [3] Unknown CD Unknown Unkn
CT, computerized tomography; MRI, magnetic resonance imaging; CD, Crohn’s diseaprednisone and adalimumab and the patient has been
asymptomatic on adalimumab for 10 months with no re-
currence of the OM.
Discussion
OM is a very rare extraintestinal manifestation of in-
flammatory bowel disease and is more common in CD
than ulcerative colitis [10]. Seventeen previous cases of
CD associated OM and three previous cases of UC re-
lated OM have been reported in literature. The clinical
specifics related to these published case reports are sum-
marized in Table 1.
OM is inflammation of one or more extraocular mus-
cles and generally presents with the mass effect of the
inflammation, leading to orbital swelling, proptosis, diplo-









Infliximab methylprednisone Resolved 13 months
linium MRI Infliximab prednisolone Resolved 24 months
Adalimumab Resolved 36 months
RI Corticosteroid Resolved Unknown







Prednisolone oral antibiotics Resolved 3 months
RI Corticosteroids Resolved 12 months
Infliximab methotrexate Resolved 27 months


















own Coricosteroids Colectomy Resolved 2.5 months







own Unknown Unknown Unknown
se; UC, ulcerative colitis.
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to that of thyroid ophthalmopathy and as such, the patho-
genesis needs to be determined early at presentation. Thy-
roid eye disease is typically bilateral, retracted eyelids, and
has more involvement of the inferior and medial rectus
while sparing tendonous insertions and appearing spin-
dle shaped on imaging [10,23]. In contrast, in OM asso-
ciated with CD there is a tubular configuration on
imaging reflecting involvement of tendonous insertion
[24]. Furthermore, thyroid ophthalmopathy usually does
not cause pain as is the case in OM. The pathophysi-
ology of CD associated OM remains unknown, but it
has been hypothesized that immune complexes form to
antigenic colonic mucoproteins and may cross react with
extraocular muscles [21].
OM has been described to occur prior to the devel-
opment of Crohn’s related gastrointestinal symptoms
[7], and when the CD is in remission [9]. To our know-
ledge this is the first case that demonstrates OM occur-
ring in a patient in clinical and biochemical remission
after discontinuation of anti-TNFα therapy. The fact
that the onset of the OM occurred 13 weeks after stop-
ping infliximab is in keeping with the known infliximab
pharmacokinetics [25].
Treatment of CD associated OM has traditionally in-
volved corticosteroids as first line therapy, and low
dose orbital radiotherapy, methotrexate, cyclosporine,
and cyclophosphamide as second line therapies [26,27].
While the immediate inflammatory phase of OM is
frequently corticosteroid responsive recurrences may
occur once the dose is tapered [5]. Indeed, prior to
the frequent use of immunosuppressive or anti-TNFα
therapy for CD OM recurrence was common (Table 1).
Since the patient in this case report presented with
OM after discontinuation of infliximab, there was sig-
nificant risk of recurrent OM once his corticosteroid
treatment tapered to zero. Infliximab was used to suc-
cessfully control chronic recurrent OM in 4 patients
with inflammatory bowel disease (Table 1) and 3 non-
inflammatory bowel disease patients who all failed
standard treatment [14]. Adalimumab was successfully
utilized to treat OM in a single patient with CD who
had recurrent episodes and who failed to respond to
standard immunosuppression medication (Table 1) [6]
and in one non-inflammatory bowel disease-related
case [5]. Mouse chimeric nature of infliximab may lead
to the development of autoantibodies and result in
blunting of the clinical response and development of
adverse reactions. Adalimumab, with a fully humanized
molecular structure may not elicit the same autoantibody
response. The CARE study efficacy of adalimumab for
extraintestinal manifestations of CD and found that there
is no significant difference in EIM resolution based on
previous infliximab exposure [28].Conclusion
The current case demonstrates a rare extraintestinal
manifestation of CD, OM and its temporal relationship
to the discontinuance of infliximab therapy and its suc-
cessful treatment, without recurrence (for 10 months at
the time of this publication), with tapering prednisone
and adalimumab. Clinicians should be cognizant of this
rare extraintestinal manifestation of CD that can occur
in the absence of luminal disease activity, its propensity
for recurrence and its successful response to anti-TNFα
therapy.
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